Cargando…

A nationwide cross-sectional analysis of biopsy-proven Fabry nephropathy: the Japan Renal Biopsy Registry

BACKGROUND: Fabry disease (FD) is an X-linked inherited disease where renal complications are associated with a poor prognosis. However, little is known about the prevalence of Fabry nephropathy (FN) in patients with chronic kidney disease (CKD). We extracted FN data from the Japan Renal Biopsy Regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasu, Makoto, Nakagawa, Naoki, Hara, Shigeo, Yano, Junko, Kurokawa, Yuka, Nakamura, Nao, Yokoyama, Hitoshi, Shimizu, Akira, Sugiyama, Hitoshi, Sato, Hiroshi, Fukami, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845163/
https://www.ncbi.nlm.nih.gov/pubmed/36329296
http://dx.doi.org/10.1007/s10157-022-02287-w
_version_ 1784870832218046464
author Nasu, Makoto
Nakagawa, Naoki
Hara, Shigeo
Yano, Junko
Kurokawa, Yuka
Nakamura, Nao
Yokoyama, Hitoshi
Shimizu, Akira
Sugiyama, Hitoshi
Sato, Hiroshi
Fukami, Kei
author_facet Nasu, Makoto
Nakagawa, Naoki
Hara, Shigeo
Yano, Junko
Kurokawa, Yuka
Nakamura, Nao
Yokoyama, Hitoshi
Shimizu, Akira
Sugiyama, Hitoshi
Sato, Hiroshi
Fukami, Kei
author_sort Nasu, Makoto
collection PubMed
description BACKGROUND: Fabry disease (FD) is an X-linked inherited disease where renal complications are associated with a poor prognosis. However, little is known about the prevalence of Fabry nephropathy (FN) in patients with chronic kidney disease (CKD). We extracted FN data from the Japan Renal Biopsy Registry, analyzed the prevalence of FN, and examined the correlation between clinical characteristics and renal involvement according to sex differences and hemi- and heterozygosity in patients with FD. METHODS: A total of 38,351 participants who underwent renal biopsy were retrospectively enrolled, and FN was determined. The clinical characteristics of FD patients were examined based on sex differences. RESULTS: Twenty-nine patients (0.076%) (19 males and 10 females, mean age: 43.7 ± 15.5 years old) were diagnosed with FN. Median estimated urinary protein (UP) and mean eGFR levels were 0.9 [interquartile range (IQR) [0.7–1.6] g/gCr and 67.1 ± 36.8 mL/min/1.73 m(2), respectively. Mean systolic blood pressure (SBP) was 126.4 ± 17.1 mmHg and diastolic blood pressure was 76.1 ± 12.6 mmHg. An inverse correlation between eGFR and logarithm UP levels was observed (r(2) = 0.23, p = 0.02), SBP was positively associated with logarithm UP (r(2) = 0.34, p = 0.004) overall and inversely associated with eGFR (r(2) = 0.25, p = 0.007) regardless of sex, and SBP was an independent determinant of proteinuria (p = 0.004) and eGFR (p = 0.007). CONCLUSIONS: The prevalence of biopsy-proven FN was 0.076%. Since SBP is associated with eGFR regardless of zygosity, strict SBP control might be necessary to prevent progression to end-stage kidney disease in both male and female patients with FN. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10157-022-02287-w.
format Online
Article
Text
id pubmed-9845163
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-98451632023-01-19 A nationwide cross-sectional analysis of biopsy-proven Fabry nephropathy: the Japan Renal Biopsy Registry Nasu, Makoto Nakagawa, Naoki Hara, Shigeo Yano, Junko Kurokawa, Yuka Nakamura, Nao Yokoyama, Hitoshi Shimizu, Akira Sugiyama, Hitoshi Sato, Hiroshi Fukami, Kei Clin Exp Nephrol Original Article BACKGROUND: Fabry disease (FD) is an X-linked inherited disease where renal complications are associated with a poor prognosis. However, little is known about the prevalence of Fabry nephropathy (FN) in patients with chronic kidney disease (CKD). We extracted FN data from the Japan Renal Biopsy Registry, analyzed the prevalence of FN, and examined the correlation between clinical characteristics and renal involvement according to sex differences and hemi- and heterozygosity in patients with FD. METHODS: A total of 38,351 participants who underwent renal biopsy were retrospectively enrolled, and FN was determined. The clinical characteristics of FD patients were examined based on sex differences. RESULTS: Twenty-nine patients (0.076%) (19 males and 10 females, mean age: 43.7 ± 15.5 years old) were diagnosed with FN. Median estimated urinary protein (UP) and mean eGFR levels were 0.9 [interquartile range (IQR) [0.7–1.6] g/gCr and 67.1 ± 36.8 mL/min/1.73 m(2), respectively. Mean systolic blood pressure (SBP) was 126.4 ± 17.1 mmHg and diastolic blood pressure was 76.1 ± 12.6 mmHg. An inverse correlation between eGFR and logarithm UP levels was observed (r(2) = 0.23, p = 0.02), SBP was positively associated with logarithm UP (r(2) = 0.34, p = 0.004) overall and inversely associated with eGFR (r(2) = 0.25, p = 0.007) regardless of sex, and SBP was an independent determinant of proteinuria (p = 0.004) and eGFR (p = 0.007). CONCLUSIONS: The prevalence of biopsy-proven FN was 0.076%. Since SBP is associated with eGFR regardless of zygosity, strict SBP control might be necessary to prevent progression to end-stage kidney disease in both male and female patients with FN. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10157-022-02287-w. Springer Nature Singapore 2022-11-03 2023 /pmc/articles/PMC9845163/ /pubmed/36329296 http://dx.doi.org/10.1007/s10157-022-02287-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Nasu, Makoto
Nakagawa, Naoki
Hara, Shigeo
Yano, Junko
Kurokawa, Yuka
Nakamura, Nao
Yokoyama, Hitoshi
Shimizu, Akira
Sugiyama, Hitoshi
Sato, Hiroshi
Fukami, Kei
A nationwide cross-sectional analysis of biopsy-proven Fabry nephropathy: the Japan Renal Biopsy Registry
title A nationwide cross-sectional analysis of biopsy-proven Fabry nephropathy: the Japan Renal Biopsy Registry
title_full A nationwide cross-sectional analysis of biopsy-proven Fabry nephropathy: the Japan Renal Biopsy Registry
title_fullStr A nationwide cross-sectional analysis of biopsy-proven Fabry nephropathy: the Japan Renal Biopsy Registry
title_full_unstemmed A nationwide cross-sectional analysis of biopsy-proven Fabry nephropathy: the Japan Renal Biopsy Registry
title_short A nationwide cross-sectional analysis of biopsy-proven Fabry nephropathy: the Japan Renal Biopsy Registry
title_sort nationwide cross-sectional analysis of biopsy-proven fabry nephropathy: the japan renal biopsy registry
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845163/
https://www.ncbi.nlm.nih.gov/pubmed/36329296
http://dx.doi.org/10.1007/s10157-022-02287-w
work_keys_str_mv AT nasumakoto anationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT nakagawanaoki anationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT harashigeo anationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT yanojunko anationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT kurokawayuka anationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT nakamuranao anationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT yokoyamahitoshi anationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT shimizuakira anationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT sugiyamahitoshi anationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT satohiroshi anationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT fukamikei anationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT nasumakoto nationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT nakagawanaoki nationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT harashigeo nationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT yanojunko nationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT kurokawayuka nationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT nakamuranao nationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT yokoyamahitoshi nationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT shimizuakira nationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT sugiyamahitoshi nationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT satohiroshi nationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry
AT fukamikei nationwidecrosssectionalanalysisofbiopsyprovenfabrynephropathythejapanrenalbiopsyregistry